These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21045143)

  • 1. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.
    Kuroda S; Fujiwara T; Shirakawa Y; Yamasaki Y; Yano S; Uno F; Tazawa H; Hashimoto Y; Watanabe Y; Noma K; Urata Y; Kagawa S; Fujiwara T
    Cancer Res; 2010 Nov; 70(22):9339-48. PubMed ID: 21045143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase-specific oncolytic adenovirus: antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells.
    Takahashi H; Hyakusoku H; Horii C; Takahashi M; Nishimura G; Taguchi T; Kondo N; Sakakibara A; Urata Y; Sano D
    Head Neck; 2014 Mar; 36(3):411-8. PubMed ID: 23728900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.
    Rajecki M; af Hällström T; Hakkarainen T; Nokisalmi P; Hautaniemi S; Nieminen AI; Tenhunen M; Rantanen V; Desmond RA; Chen DT; Guse K; Stenman UH; Gargini R; Kapanen M; Klefström J; Kanerva A; Pesonen S; Ahtiainen L; Hemminki A
    Int J Cancer; 2009 Nov; 125(10):2441-9. PubMed ID: 19672857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular redistribution and modification of proteins of the Mre11/Rad50/Nbs1 DNA repair complex following irradiation and heat-shock.
    Seno JD; Dynlacht JR
    J Cell Physiol; 2004 May; 199(2):157-70. PubMed ID: 15039997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Rad50 sensitizes human nasopharyngeal carcinoma cells to radiotherapy.
    Chang L; Huang J; Wang K; Li J; Yan R; Zhu L; Ye J; Wu X; Zhuang S; Li D; Zhang G
    BMC Cancer; 2016 Mar; 16():190. PubMed ID: 26951044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
    Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
    Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase-specific virotheranostics for human head and neck cancer.
    Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
    Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.
    Li G; Kawashima H; Ogose A; Ariizumi T; Xu Y; Hotta T; Urata Y; Fujiwara T; Endo N
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):1037-51. PubMed ID: 21193997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression.
    Omori T; Tazawa H; Yamakawa Y; Osaki S; Hasei J; Sugiu K; Komatsubara T; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    PLoS One; 2021; 16(4):e0250643. PubMed ID: 33886686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer.
    Fujiwara T
    Acta Med Okayama; 2011 Jun; 65(3):151-62. PubMed ID: 21709712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template.
    Williams RS; Williams JS; Tainer JA
    Biochem Cell Biol; 2007 Aug; 85(4):509-20. PubMed ID: 17713585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer.
    Sakai R; Kagawa S; Yamasaki Y; Kojima T; Uno F; Hashimoto Y; Watanabe Y; Urata Y; Tanaka N; Fujiwara T
    Mol Cancer Ther; 2010 Jun; 9(6):1884-93. PubMed ID: 20501801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization.
    Kuroda S; Urata Y; Fujiwara T
    Acta Med Okayama; 2012; 66(2):83-92. PubMed ID: 22525466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect.
    Kim J; Kim PH; Yoo JY; Yoon AR; Choi HJ; Seong J; Kim IW; Kim JH; Yun CO
    Gene Ther; 2009 Sep; 16(9):1111-21. PubMed ID: 19494843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.